Preoperative lymphocyte count is an independent prognostic factor in node-negative non-small cell lung cancer

Lung Cancer

Volumn 75, Issue 2, 2012, Pages 223-227

  Kobayashi, Naohiro ^a   Usui, Shingo ^a   Kikuchi, Shinji ^a   Goto, Yukinobu ^a   Sakai, Mitsuaki ^a   Onizuka, Masataka ^a   Sato, Yukio ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Lymphocyte count; Neutrophil count; Node negative; Non small cell lung cancer; Prognostic factor; Vascular invasion

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INVASION; CANCER RECURRENCE; CANCER SIZE; CANCER STAGING; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LOG RANK TEST; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PLEURA INVASION; PREDICTIVE VALUE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; VASCULAR INVASION;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84855464641     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2011.06.009     Document Type: Article

References (37)

1. Suzuki K., Nagai K., Yoshida J., Nishimura M., Takahashi K., Yokose T., et al. Conventional clinicopathologic prognostic factors in surgically resected nonsmall cell lung carcinoma. A comparison of prognostic factors for each pathologic TNM stage based on multivariate analyses. Cancer 1999, 86:1976-1984.
2. Mountain C.F. Lung cancer staging classification. Clin Chest Med 1993, 14:43-53.
3. Naruke T., Goya T., Tsuchiya R., Suemasu K. Prognosis and survival in resected lung carcinoma based on the new international staging system. J Thorac Cardiovasc Surg 1988, 96:440-447.
4. Paesmans M., Sculier J.P., Libert P., Bureau G., Dabouis G., Thiriaux J., et al. Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party. J Clin Oncol 1995, 13:1221-1230.
5. Forrest L.M., McMillan D.C., McArdle C.S., Angerson W.J., Dunlop D.J. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer 2003, 89:1028-1030.
6. O'Dowd C., McRae L.A., McMillan D.C., Kirk A., Milroy R. Elevated preoperative C-reactive protein predicts poor cancer specific survival in patients undergoing resection for non-small cell lung cancer. J Thorac Oncol 2010, 5:988-992.
7. Scott H.R., McMillan D.C., Forrest L.M., Brown D.J., McArdle C.S., Milroy R. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 2002, 87:264-267.
8. Walsh S.R., Cook E.J., Goulder F., Justin T.A., Keeling N.J. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 2005, 91:181-184.
9. Halazun K.J., Aldoori A., Malik H.Z., Al-Mukhtar A., Prasad K.R., Toogood G.J., et al. Elevated preoperative neutrophil to lymphocyte ratio predicts survival following hepatic resection for colorectal liver metastases. Eur J Surg Oncol 2008, 34:55-60.
10. Hirashima M., Higuchi S., Sakamoto K., Nishiyama T., Okada H. The ratio of neutrophils to lymphocytes and the phenotypes of neutrophils in patients with early gastric cancer. J Cancer Res Clin Oncol 1998, 124:329-334.
11. Yamanaka T., Matsumoto S., Teramukai S., Ishiwata R., Nagai Y., Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007, 73:215-220.
12. Sarraf K.M., Belcher E., Raevsky E., Nicholson A.G., Goldstraw P., Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 2009, 137:425-428.
13. Teramukai S., Kitano T., Kishida Y., Kawahara M., Kubota K., Komuta K., et al. Pretreatment neutrophil count as an independent prognostic factor in advanced non-small-cell lung cancer: an analysis of Japan Multinational Trial Organisation LC00-03. Eur J Cancer 2009, 45:1950-1958.
14. Wislez M., Antoine M., Rabbe N., Gounant V., Poulot V., Lavole A., et al. Neutrophils promote aerogenous spread of lung adenocarcinoma with bronchioloalveolar carcinoma features. Clin Cancer Res 2007, 13:3518-3527.
15. Lissoni P., Brivio F., Fumagalli L., Messina G., Ghezzi V., Frontini L., et al. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors. Int J Biol Markers 2004, 19:135-140.
16. World Health Organization Tumours of the lung. Tumours of the lung, pleura, thymus and heart 2004, 10. International Agency for Research on Cancer, Lyon.
17. Sobin L.H., Gospodarowicz M.K., Wittekind C. International Union Against Cancer (UICC): TNM classification of malignant tumours 2010, John Willkey and Sons Ltd., UK. 7th ed.
18. Takahashi H., Kurishima K., Ishikawa H., Kagohashi K., Kawaguchi M., Satoh H. Optimal cutoff points of CYFRA21-1 for survival prediction in non-small cell lung cancer patients based on running statistical analysis. Anticancer Res 2010, 30:3833-3837.
19. Fogar P., Sperti C., Basso D., Sanzari M.C., Greco E., Davoli C., et al. Decreased total lymphocyte counts in pancreatic cancer: an index of adverse outcome. Pancreas 2006, 32:22-28.
20. Clark E.J., Connor S., Taylor M.A., Madhavan K.K., Garden O.J., Parks R.W. Preoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinoma. HPB (Oxford) 2007, 9:456-460.
21. Ownby H.E., Roi L.D., Isenberg R.R., Brennan M.J. Peripheral lymphocyte and eosinophil counts as indicators of prognosis in primary breast cancer. Cancer 1983, 52:126-130.
22. Hespanhol V., Queiroga H., Magalhaes A., Santos A.R., Coelho M., Marques A. Survival predictors in advanced non-small cell lung cancer. Lung Cancer 1995, 13:253-267.
23. Muers M.F., Shevlin P., Brown J. Prognosis in lung cancer: physicians' opinions compared with outcome and a predictive model. Thorax 1996, 51:894-902.
24. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
25. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
26. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
27. Tormanen-Napankangas U., Soini Y., Paakko P. High number of tumour-infiltrating lymphocytes is associated with apoptosis in non-small cell lung carcinoma. APMIS 2001, 109:525-532.
28. Donnem T., Al-Shibli K., Andersen S., Al-Saad S., Busund L.T., Bremnes R.M. Combination of low vascular endothelial growth factor A (VEGF-A)/VEGF receptor 2 expression and high lymphocyte infiltration is a strong and independent favorable prognostic factor in patients with nonsmall cell lung cancer. Cancer 2010, 116:4318-4325.
29. Hiraoka K., Miyamoto M., Cho Y., Suzuoki M., Oshikiri T., Nakakubo Y., et al. Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma. Br J Cancer 2006, 94:275-280.
30. + T cells in cancer cell nests, are associated with favorable prognosis in human non-small cell lung cancers. Cancer Sci 2003, 94:1003-1009.
31. Al-Shibli K.I., Donnem T., Al-Saad S., Persson M., Bremnes R.M., Busund L.T. Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer. Clin Cancer Res 2008, 14:5220-5227.
32. Ruffini E., Asioli S., Filosso P.L., Lyberis P., Bruna M.C., Macri L., et al. Clinical significance of tumor-infiltrating lymphocytes in lung neoplasms. Ann Thorac Surg 2009, 87:365-371. discussion 371-72.
33. Kataki A., Scheid P., Piet M., Marie B., Martinet N., Martinet Y., et al. Tumor infiltrating lymphocytes and macrophages have a potential dual role in lung cancer by supporting both host-defense and tumor progression. J Lab Clin Med 2002, 140:320-328.
34. Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N., et al. Immunologic parameters as significant prognostic factors in lung cancer. Lung Cancer 2002, 37:161-169.
35. Gabor S., Renner H., Popper H., Anegg U., Sankin O., Matzi V., et al. Invasion of blood vessels as significant prognostic factor in radically resected T1-3N0M0 non-small-cell lung cancer. Eur J Cardiothorac Surg 2004, 25:439-442.
36. Espinosa E., Feliu J., Zamora P., Gonzalez Baron M., Sanchez J.J., Ordon ez A., et al. Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 1995, 12:67-76.
37. Gupta D., Lis C.G. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J 2010, 9:69.